This study reports 2-year survival outcomes among patients with advanced nonprogressive stage IIA to IV lung cancer randomized to symptom monitoring during chemotherapy via web-based patient-reported outcomes vs standard scheduled imaging after treatment to detect symptomatic recurrence.
